<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Pfizer’s Begins Clinical Trials for Antiviral
Image Overlay - Pfizer’s Begins Clinical Trials for Antiviral

Pfizer’s Begins Clinical Trials for Antiviral

September 22, 2020

Pfizer’s Begins Clinical Trials for Antiviral

Pfizer has initiated Phase 1 clinical tests of PF-07304814, a small molecule that could be used in the fight against SARS-CoV-2, which causes COVID-19. The drug targets the 3CL protease, an enzyme that allows the virus to multiply. If approved, PF-07304814 would be the first antiviral drug to target this protein. With 21 strategically located global depots, Yourway can fully support global trial needs around the world.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Media

Articles

White-Glove by Design: The Yourway Standard in Clinical Logistics

Open chat
Come chat with us!
Hello! How can I help you?